Tagworks Pharmaceuticals

About Tagworks Pharmaceuticals

Tagworks Pharmaceuticals is a pioneer in Click-to-Release technology, utilizing in vivo click chemistry to enhance the efficacy and reduce toxicity of systemic treatment modalities. Their mission is to develop safe and effective treatments for patients by enabling controlled drug release and expanding therapeutic applications.

Products & Services

Click-to-Release Technology:A leading technology for controlled drug release via in vivo click reactions with trigger molecules, aimed at increasing the therapeutic window of potent systemic therapies like antibody-drug conjugates (ADCs) and immunomodulators.

TGW101:A lead program featuring a click-cleavable ADC targeting TAG72, a non-internalizing target in solid tumors, designed to expand ADC applications and address heterogeneous tumor expression.

TGW211:A first-in-class HER2-directed radioimmunoconjugate for the treatment of HER2+ tumors, developed using the Click-to-Release platform.

Specialties

Click-to-Release Technology In Vivo Click Chemistry Antibody-Drug Conjugates (ADCs) Radiopharmaceuticals Immunomodulators Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 65000000 MR: - FA: $65 million FAN: 65000000	D: 2023-06-22 FD: 2023-06-22	7 investors

Series A Latest

2023-06-22

$65.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Carolyn Bertozzi

Nobel Prize Winner

M

Morten Meldal

B

Barry Sharpless

J

Joseph Fox

K

Ken Mills

CEO

M

Marc Robillard

CSO

View 15 more team members with Pro

Unlock Full Team Directory

Recent News